Ignite Creation Date:
2025-12-25 @ 2:52 AM
Ignite Modification Date:
2026-03-08 @ 11:01 PM
Study NCT ID:
NCT06028633
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-09-13
First Post:
2023-08-22
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients
Sponsor:
Peking University First Hospital
Organization: